Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clinical Metabolomics Inc.

Sharpening clinical trials with metabolomics

This article was originally published in Start Up

Executive Summary

Pharma has had trouble developing therapeutics for diabetic kidney disease because of its slow disease process – it can take months or years to demonstrate an improvement in kidney function in response to a drug. Researchers at Clinical Metabolomics Inc. (doing business as ClinMet) think their technology for monitoring kidney function through metabolites found in the urine can speed clinical trials by identifying signs of kidney improvement, and the research also has led to a new insight into the underlying causes of DKD that could lead to new therapies.



Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts